Dagmar D.
- Country
- Germany
- Department
- Zentrum für Kinder- und Jugendmedizin Abt. Päd. Hämatologie/Onkologie
Research Overview
- Evaluation of Melphalan-Based Chemotherapy Regimens in Low and Intermediate Risk Neuroblastoma: A Multicenter, Prospective Study
- Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
- Phase II Randomized Study of Bortezomib with Dexamethasone, Mitoxantrone, Vincristine, Pegaspargase, and Methotrexate in High-Risk Relapsed Pediatric ALL
Data & Insights
Has run more than one trial at 60 of 137 partner sites.
Specializations
Pediatric Oncology
The investigator specializes in treating childhood cancers, with particular expertise in hematologic malignancies and solid tumors affecting young patients.
- Acute Lymphoblastic Leukemia (ALL)
- B-cell lymphomas and leukemias
- Neuroblastoma
Their work encompasses both newly diagnosed cases and relapsed disease scenarios in pediatric populations.
Advanced Therapeutics
The investigator focuses on developing innovative treatment approaches for pediatric cancers, including immunotherapy and targeted therapies.
- Stem Cell Transplantation
- Rituximab-based treatments
- EBV-positive carcinoma therapies
Their research integrates novel therapeutic agents with established treatment protocols to enhance patient outcomes.
Treatment Optimization
The investigator works on risk-adapted therapeutic strategies and treatment modifications to improve efficacy while minimizing toxicity.
- Radiation therapy optimization
- Risk-based treatment stratification
- Response assessment protocols
Their approach focuses on personalizing treatment intensities based on individual patient risk factors and response patterns.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.